Antibody Cascade Design Key to Customizing Success

MICHELE WILSON PHD | January 28, 2019

article image
Last November, Abcam’s Head of Customs Services, Jamie Campbell, presented at the PEGS (Protein & Antibody Engineering Summit) Europe conference in Lisbon, Portugal. We caught up with Jamie to get a rundown on his talk, which covered the company’s approach to discovering antibodies – key reagents in drug discovery, in vitro diagnostics and therapeutics. Jamie gives us an outline of their RabMAb® technology, next generation sequencing platform, and phage display, and highlights current trends and opportunities in the field.

Spotlight

Mitotech LLC

Mitotech LLC is the hub company of biotech project "Skulachev ions". The company goal is to develop and market set of innovative pharmaceuticals based on new type of biologically active compounds - mitochondrially targeted antioxidants SkQ. Investors of the company is RUSNANO (Russian state corporation of nanotechnologies - www.rusnano.com) and Rostok Group (private foundation - www.grostok.ru).

OTHER ARTICLES

Pfizer, BioNTech Plan Clinical Trial for COVID-19 mRNA Vaccine Candidate

Article | April 9, 2020

Pfizer and BioNTech plan to begin human clinical trials on their lead COVID-19 therapeutic candidate, an mRNA vaccine, by the end of this month, the companies said today, through a collaboration that could generate up to $748 million for the German biotech. The companies announced plans last month to partner on BNT162, the first treatment to emerge from BioNTech’s accelerated COVID-19-focused development program, “Project Lightspeed.” BioNTech and Pfizer established collaboration intended to draw upon BioNTech’s proprietary mRNA vaccine platforms, and Pfizer’s expertise in vaccine research and development, regulatory capabilities, and global manufacturing and distribution network.

Read More

2 Small-Cap Biotech Stocks You Haven't Heard of, But Should Know About

Article | April 9, 2020

With everything that's going on with the COVID-19 pandemic, many healthcare companies have grabbed plenty of spotlight during these challenging times. At the same time, a number of otherwise promising businesses have slipped under the radar. That's especially true for small-cap biotech stocks that aren't actively involved in developing tests, vaccines or treatments for COVID-19. Vaccine developers, protective equipment producers, and healthcare service providers are all attracting plenty of attention during this pandemic, but there are just as many promising biotech stocks that aren't involved in these areas. Here are two such companies that you might have missed, but they deserve a spot on your watch list.

Read More

Closing bacterial genomes from the human gut microbiome using long-read sequencing

Article | April 9, 2020

In our lab, we focus on the impact of the gut microbiome on human health and disease. To evaluate this relationship, it’s important to understand the particular functions that different bacteria have. As bacteria are able to exchange, duplicate, and rearrange their genes in ways that directly affect their phenotypes, complete bacterial genomes assembled directly from human samples are essential to understand the strain variation and potential functions of the bacteria we host. Advances in the microbiome space have allowed for the de novo assembly of microbial genomes directly from metagenomes via short-read sequencing, assembly of reads into contigs, and binning of contigs into putative genome drafts. This is advantageous because it allows us to discover microbes without culturing them, directly from human samples and without reference databases. In the past year, there have been a number of tour de force efforts to broadly characterize the human gut microbiota through the creation of such metagenome-assembled genomes (MAGs)[1–4]. These works have produced hundreds of thousands of microbial genomes that vastly increase our understanding of the human gut. However, challenges in the assembly of short reads has limited our ability to correctly assemble repeated genomic elements and place them into genomic context. Thus, existing MAGs are often fragmented and do not include mobile genetic elements, 16S rRNA sequences, and other elements that are repeated or have high identity within and across bacterial genomes.

Read More

Top 10 biotech IPOs in 2019

Article | April 9, 2020

The big question at the start of 2019 was whether the IPO window would stay open for biotech companies, particularly those seeking to pull off ever-larger IPOs at increasingly earlier stages of development. The short answer is yes—kind of. Here’s the long answer: In the words of Renaissance Capital, the IPO market had “a mostly good year.” The total number of deals fell to 159 from 192 the year before, but technology and healthcare companies were standout performers. The latter—which include biotech, medtech and diagnostics companies—led the pack, making up 43% of all IPOs in 2019. By Renaissance’s count, seven companies went public at valuations exceeding $1 billion, up from five the year before

Read More

Spotlight

Mitotech LLC

Mitotech LLC is the hub company of biotech project "Skulachev ions". The company goal is to develop and market set of innovative pharmaceuticals based on new type of biologically active compounds - mitochondrially targeted antioxidants SkQ. Investors of the company is RUSNANO (Russian state corporation of nanotechnologies - www.rusnano.com) and Rostok Group (private foundation - www.grostok.ru).

Events